esc

Type at least two characters to start searching.

↑↓ select↵ openesc close

Share

Export Citation

APA
MLA
Chicago
Harvard
Vancouver
BIBTEX
RIS
Universitas Hasanuddin
Research output:Contribution to journal›Article›peer-review

Serum lactate dehydrogenase and vascular endothelial growth factor A level as a predictor of treatment response in locally advanced-stage World Health Organisation type 3 nasopharyngeal carcinoma

Sulaksana M.A.

Wspolczesna Onkologia

Q3
Published: 2026

Abstract

Introduction: This study aims to evaluate the association of baseline serum vascular endothelial growth factor A (VEGF-A) and lactate dehydrogenase (LDH) levels with subsequent response to sequential neoadjuvant chemotherapy followed by radiotherapy in patients with locally advanced-stage nasopharyngeal carcinoma (LA-NPC).Material and methods: A prospective nested case-control study using consecutive sampling with an outcome-based quota cap was conducted involving patients with World Health Organisation type 3 NPC, stage III-IVA.Patients were treated with three cycles of taxane-cisplatin-based neoadjuvant chemotherapy followed sequentially by definitive intensity-modulated radiotherapy.Serum VEGF-A and total LDH levels were measured prior to therapy using enzyme-linked immunosorbent assay.Treatment response was assessed using Response Evaluation Criteria in Solid Tumours 1.1 criteria at a fixed time point of 8 weeks after the completion of all planned treatment, and categorised as positive (complete or partial response) or negative (stable or progressive disease).Statistical analyses including bivariate testing, receiver operating characteristic analysis, and multivariate logistic regression.Results: A total of 58 patients were analysed.In univariate binary logistic regression assessments, high exploratory baseline serum VEGF-A (≥ 128.525 ng/l; p = 0.011) and LDH (≥ 66.485 U/l; p = 0.009) levels were significantly associated with subsequent negative treatment response.In a pre-specified multivariable model adjusted for age and VEGF-A, an elevated baseline total LDH level remained a significant independent predictor of treatment non-responsiveness (adjusted OR = 4.68; 95% CI: 1.46-15.00;p = 0.009), whereas VEGF-A lost statistical significance (p = 0.257).Conclusions: Elevated baseline serum VEGF-A and LDH protein levels are associated with non-responsiveness to sequential neoadjuvant chemotherapy and radiotherapy in LA-NPC.Pre-treatment total LDH acts as a significant, independent exploratory indicator of treatment non-responsiveness.

Access to Document

10.5114/wo.2026.163811

Other files and links

Fingerprint

MedicineSciences
Nasopharyngeal carcinomaSciences
Internal medicineSciences
Vascular endothelial growth factorSciences
Lactate dehydrogenaseSciences
EndocrinologySciences
Growth factorSciences
CarcinomaSciences
DiseaseSciences
Endothelial dysfunctionSciences
OncologySciences
Vascular endothelial growth factor ASciences
EndotheliumSciences
VEGF receptorsSciences
Risk factorSciences
CancerSciences
ImmunologySciences
L-Lactate dehydrogenaseSciences
AngiogenesisSciences
Nasopharyngeal cancerSciences